SCHEMBL24329422

SCHEMBL24329422

NCc1ccc2c3c(cccc13)C(=O)N2C1CCC(=O)NC1=O

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 18/20 0.56
DDB1 Q16531 17/20 0.56
IKZF3 Q9UKT9 2/20 0.56
ALDH1A1 P00352 1/20 0.56
CHRM2 P08172 1/20 0.56
OPRM1 P35372 1/20 0.56
CYP1A2 P05177 1/20 0.56
TSHR P16473 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
TNF P01375 1/20 0.54
IL1B P01584 1/20 0.54
TBXA2R P21731 1/20 0.54
IKZF1 Q13422 1/20 0.54
BCL2L11 O43521 1/20 0.51
BCL2 P10415 1/20 0.51
MCL1 Q07820 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24329419 1.00 CRBN (0.56) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL30273700 1.00 CRBN (0.56) CRBNDDB1IKZF3ALDH1A1CHRM2
Hydrochloric Acid SCHEMBL26691511 0.99 CRBN (0.55) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL29533020 0.96 CRBN (0.53) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24317632 0.96 CRBN (0.53) CRBNDDB1IKZF3ALDH1A1CHRM2
Hydrochloric Acid SCHEMBL26691522 0.95 CRBN (0.52) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL25672861 0.91 DDB1 (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL25672912 0.91 DDB1 (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL25672886 0.91 DDB1 (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL23540050 0.90 CRBN (0.52) CRBNDDB1IKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 US disclosed
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 US disclosed
WO-2022271727-A1 DEGRADER COMPOUNDS AND USES THEREOF CALICO LIFE SCIENCES LLC (US) 2022-12-29 WO disclosed
WO-2022081928-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS CRBN, CDR2, MDM2 CRBN 1/4885DDB1 165/4885IKZF3 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.